Thomas Nicholson - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Thomas Nicholson

Showing results (51-60 of 53) with videos related to

Pageof 6

Sort By:

You have reached the last page of results.This site can display upto 53 results.

Plos One|June 17, 2026

REPROGRAM: REsilience PROmotion with GeRoprotectors: AssessMent of biological effect: Rationale and protocol for a trial of biological effectDaisy Wilson, Animesh Acharjee, Niharika A Duggal, et al.

Scientific Reports|July 22, 2021

PAX8 lineage-driven T cell engaging antibody for the treatment of high-grade serous ovarian cancerEmily Lee, Sarah Szvetecz, Ryan Polli, et al.

Nature Cell Biology|October 21, 2014

Selective VPS34 inhibitor blocks autophagy and uncovers a role for NCOA4 in ferritin degradation and iron homeostasis in vivoWilliam E Dowdle, Beat Nyfeler, Jane Nagel, et al.

Pageof 6

Search research articles

Showing results (51-60 of 53) with videos related to

Sort By:

Pageof 6

You have reached the last page of results.This site can display upto 53 results.

Plos One|June 17, 2026

REPROGRAM: REsilience PROmotion with GeRoprotectors: AssessMent of biological effect: Rationale and protocol for a trial of biological effectDaisy Wilson, Animesh Acharjee, Niharika A Duggal, et al.

Scientific Reports|July 22, 2021

PAX8 lineage-driven T cell engaging antibody for the treatment of high-grade serous ovarian cancerEmily Lee, Sarah Szvetecz, Ryan Polli, et al.

Nature Cell Biology|October 21, 2014

Selective VPS34 inhibitor blocks autophagy and uncovers a role for NCOA4 in ferritin degradation and iron homeostasis in vivoWilliam E Dowdle, Beat Nyfeler, Jane Nagel, et al.

Pageof 6